Samsung Biologics stock gets a new contract through 2031

Published on 10/05/2026 at 20:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Samsung Biologics stock closed at KRW 1,354,000 on October 2, 2026, after a KRW 93,478,620,000 contract. Second-quarter revenue rose 30 percent and operating profit 23 percent year over year.

Samsung Biologics, KR7207940008, Illustration mit AI erstellt.

Samsung Biologics (ISIN KR7207940008) closed at KRW 1,354,000 on the KRX on October 2, 2026, after signing a KRW 93,478,620,000 manufacturing contract with a European pharmaceutical company. According to Aju Press on October 2, the agreement runs through December 31, 2031 and represents 2.05 percent of the company revenue reported at the end of 2025.

Contract strengthens the order pipeline

The undisclosed European customer will receive contract manufacturing services under the agreement, while the identity of the counterparty is scheduled for disclosure at the end of the contract. The value gives Samsung Biologics another quantified demand signal as its production network expands.

The contract also arrives alongside a broader push for new customers. CHOSUNBIZ reported that Samsung Biologics plans to present its CDMO capabilities at four events in October, including BioJapan, CPHI Milan, World ADC San Diego and BioPlus INTERPHEX Korea.

Quarterly growth remains substantial

Samsung Biologics recorded KRW 1.3209 trillion in second-quarter 2026 revenue and KRW 586.4 billion in operating profit. Health Chosun reported that revenue increased 30 percent from the same period a year earlier, while operating profit rose 23 percent.

The same report said Samsung Biologics expects to reach the upper end of its 2026 revenue-growth guidance of 15 percent to 20 percent. Plant 5 and the U.S. Rockville facility are the central operating drivers cited for the second half of the year, making execution at those sites more important than the contract headline alone.

Consensus stays above the market price

According to Investing.com, 26 analysts assign Samsung Biologics a Strong Buy consensus, with 25 Buy ratings, 1 Hold rating and 0 Sell ratings. The average 12-month price target is KRW 1,971,805, with a high of KRW 2,200,000 and a low of KRW 1,600,000, putting the average target 45.63 percent above the October 2 closing price.

The valuation gap comes with an operational risk. CHOSUNBIZ reported on October 2 that the labor union plans a three-week general strike from October 26, while a Samsung Biologics official said the previous strike caused KRW 150 billion in losses.

Stock closes below its yearly high

Samsung Biologics stock closed at KRW 1,354,000 on the KRX on October 2, 2026, down 5.25 percent from the prior close. The price stood 31.86 percent below the 52-week high of KRW 1,987,000, while the market capitalization was KRW 62.7 trillion.